Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 6457 - 6464 of 12040 results

FDA 2017 Year in Review: Therapeutic Products, Part 2
December 19, 2017| Blog| Viewpoint

National Venture Capital Association Wins Lawsuit Challenging Delay of Implementation of International Entrepreneur Parole Rule
December 19, 2017| Blog| Viewpoint

Two Supreme Court Orders Reinstate Trump’s Travel Ban
December 19, 2017| Blog| Viewpoint

Despite Presence of “Power Buyer,” FTC Obtains Preliminary Injunction of Proposed Physician Acquisition in North Dakota
December 19, 2017| Alert| Viewpoint

Federal Circuit Rules that BPCIA Preempts State Law Biosimilars Claims
December 18, 2017| Blog| Viewpoint

ML Strategies Health Care Preview - Week of December 18th
December 18, 2017| Blog| Viewpoint

FDA 2017 Year In Review: Therapeutic Products Energized by Cures Act, Bold Leadership
December 18, 2017| Blog| Viewpoint

Tax bill will lead to radical transformation of muni market
December 18, 2017| News
News & Press Releases
Mintz Welcomes Corporate Member Ruth Jin in New York
July 21, 2025
Ruth Jin has joined Mintz as a Member in the firm’s Corporate Practice with a focus on investment fund formation, liquidity strategies, governance, investment transactions, and securities offerings.
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
